7
Table 1. Emetic Risk of Single Intravenous Antineoplastic
Agents in Adults
Risk Level Agent
High
(>90%)
Anthracycline/cyclophosphamide
combination
Carmustine
Cisplatin
Cyclophosphamide >1,500 mg/m²
Dacarbazine
Mechlorethamine
Streptozocin
Moderate
(30%–90%)
Alemtuzumab
Azacitidine
Bendamustine
Carboplatin
Clofarabine
Cyclophosphamide <1,500 mg/m²
Cytarabine >1,000 mg/m²
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Ifosfamide
Irinotecan
Irinotecan liposomal injection
Oxaliplatin
Romidepsin
Temozolomide
a
iotepa
b
Trabectedin
Low
(10%–30%)
Aflibercept
Atezolizumab
Belinostat
Blinatumomab
Bortezomib
Brentuximab
Cabazitaxel
Carfilzomib
Catumaxumab
Cetuximab
Cytarabine ≤1,000 mg/m²
Docetaxel
Elotuzumab
Eribulin
Etoposide
Fluorouracil
Gemcitabine
Ipilimumab
Ixabepilone
Methotrexate
Mitomycin
Mitoxantrone
Nab-paclitaxel
Necitumumab
Paclitaxel
Panitumumab
Pemetrexed
Peg ylated liposomal
doxorubicin
Pertuzumab
Temsirolimus
Topotecan
Trastuzumab-emtansine
Vinflunine
Minimal
(<10%)
Bevacizumab
Bleomycin
Busulfan
2-Chlorodeoxyadenosine
Cladribine
Daratumumab
Fludarabine
Nivolumab
Obinutuzumab
Ofatumumab
Pembrolizumab
Pixantrone
Pralatrexate
Ramucirumab
Rituximab
Trastuzumab
Vinblastine
Vincristine
Vinorelbine
a
No direct evidence found for intravenous temozolomide. Since all sources indicate a similar safety
profile to the oral formulation, the classification was based on oral temozolomide.
b
Classification refers to individual evidence from pediatric trials.
